
A second call for proposals is being launched to characterise and validate cardiomyocytes derived from human embryonic stem cells. The call for proposals will be split into three parts: an expression of interest; a workshop on 22 October 2008 in London, to brief and answer questions from potenital applicants and the submission and review of full proposals.
The timelines for the project are:
Closing date for Expressions of Interest and registration for the Briefing Meeting, both of which should be received by 17:00.
Briefing Meeting, London - all those expressing an interest are encouraged to attend, or send a representative (registration by 10 October 2008).
Closing date for full proposals, which should be received by 17:00.
Notification of outcomes to applicants.
The first call for proposals closed in December 2007. The first call for proposals can be downloaded below for information.
Four projects were awarded for funding in the first call aimed at two key areas:
These projects will run through to the September 2009.
The call for proposals and strategy developed by Stem Cells for Safer Medicines is based upon the report by the ABPI to the Department of Health and the then Department of Trade & Industry.
The IPR policy has been developed to encourage the participation of a broad range of stakeholders, including academics, SMEs and larger external firms. The policy has been developed after broad consultation.